Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...
Novartis Pharma Maroc has appointed Yahya Abdallah as country president for its Morocco, Tunisia, and Algeria (MTA) regional ...
Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...
The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ (NOVN: VX) oral Fabhalta (iptacopan) for ...
Zacks.com on MSN2d
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...
The Swiss pharma giant – which has its U.S. headquarters in East Hanover – said it aims to encourage football fans to "proactively manage their health." ...
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback